News

Basilea is currently conducting pivotal randomized Phase III studies focusing on first-line treatment against invasive aspergillus or candida bloodstream infections. This additional supportive international multicenter safety and efficacy

The financing round was led by by Oklahoma City, Oklahoma-based venture capital investors McClendon Venture Company and TLW Venture Company. The proceeds will be utilized to finance North

The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the US after product

Natus has agreed to acquire all outstanding shares of SonaMed capital stock in a cash transaction. The agreement has received the approval of the boards of directors of

The study involves approximately 600 patients primarily in the US and Canada, with additional sites in Europe. This first efficacy study, a one-year placebo-controlled efficacy study will assess

The companies will work together to enhance the dosing profile for compounds within Amylin’s early R&D pipeline. The goal of the collaboration is to develop multiple products based

Using the complex model system chick chorioallantoic membrane (CAM), researchers observed that topical application or intravenous injection of TM601 inhibited angiogenesis (new blood vessel growth), which was stimulated

In familial hypercholesterolemia (FH) patients exposed to mipomersen for as long as 16 months, the safety profile of the drug continues to be encouraging. Reductions in low-density lipoprotein

According to PharmaTimes, the introduction of mass health insurance, liberalization initiatives and the Middle East governments’s desire to become self-sufficient in pharmaceuticals production may herald a prospective future